Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 8/20 | 0.48 |
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451058 | 0.88 | KDM4E (0.61) | CSF1RMAPK14LCKRAF1BRAF | |
| SCHEMBL6454435 | 0.78 | RPS6KB1 (0.49) | CSF1RMAPK14LCKKDRTEK | |
| SCHEMBL6455269 | 0.75 | BRAF (0.59) | CSF1RMAPK14LCKKDRTEK | |
| SCHEMBL6451067 | 0.75 | BRAF (0.59) | CSF1RMAPK14LCKKDRRAF1 | |
| SCHEMBL6451027 | 0.73 | KDM4E (0.64) | CSF1RLCKKDRRAF1BRAF | |
| SCHEMBL6450886 | 0.72 | CSF1R (0.65) | CSF1RLCKKDRRAF1BRAF | |
| SCHEMBL6454592 | 0.72 | MAPT (0.52) | KDR | |
| SCHEMBL6978589 | 0.71 | CSF1R (0.72) | CSF1RMAPK14RAF1BRAFLYN | |
| SCHEMBL6461376 | 0.71 | CSF1R (0.54) | CSF1RLCKKDRRAF1BRAF | |
| SCHEMBL6450306 | 0.71 | BTK (0.54) | CSF1RMAPK14KDRRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | claimed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | CSF1R 915/4885MAPK14 143/4885LCK 1/4885 |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | LCK, FYN, BMX | CSF1R 915/4885MAPK14 143/4885LCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.